Ontario needs biosimilars switching policy without delay

You can have confidence in your biosimilar medicines

Switching to biosimilars is safe and effective for patients

Who we are

Biosimilars Canada is a national association representing the biosimilar medicines industry in Canada. We provide leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines, and advocate for policies that support their timely approval, reimbursement, market acceptance and expanded use.

About Biosimilars

As patents for original brand biologic medicines expire other manufacturers can produce new versions called biosimilars. Health Canada authorizes biosimilars for sale using the same rigorous regulatory standards as for all other biologic drugs, and there are no clinically meaningful differences in efficacy and safety between a biosimilar and the original brand biologic medicine.

Resources

Learn more about biosimilars and their benefits for patients and healthcare systems.

Latest news

November 15, 2022

News releases

The Value of Biosimilars for Public Drug Plans

There are few solutions to such healthcare challenges that allow governments to provide more value to taxpayers for the same dollars. But that is precisely the value proposition provided through the expanded use of biosimilar medicines.

October 20, 2022

News releases

Saskatchewan Becomes Sixth Province to Implement Biosimilar Switching Initiative

Toronto – October 20, 2022 – Biosimilars Canada, a national association representing Canada’s biosimilar medicines industry, today welcomed the announcement by the Government of Saskatchewan that it will implement a “switching” or transitioning policy to expand the use of biosimilar...

October 11, 2022

News releases

“Make the switch”: Biosimilars Canada pitches Ontario on savings, benefits of switching to biosimilars

Biosimilars Canada hosted a press conference at Queen’s Park, calling on the government of Premier Doug Ford to implement a biosimilars switching policy.